Sonoma Pharmaceuticals, Inc. (DE:O8Z)
NASDAQ:O8Z
O8Z Stock Chart & Stats
€2.69
€0.00(0.00%)
At close: 4:00 PM EST
€2.69
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.69 - €2.96
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.32M
Enterprise Value€346.45K
Total Cash (Recent Filing)€2.56M
Total Debt (Recent Filing)€655.00K
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding3,473,554
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.16
Price to Sales (P/S)0.18
P/FCF Ratio-0.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.48
Revenue Forecast (FY)€20.68M
Bulls Say, Bears Say
Bulls Say
Kenvue Supply AgreementA multi-year, defined U.S. supply agreement with Kenvue provides durable commercial reach and planning visibility. The contract framework through March 2027 (plus extensions) can materially raise recurring volume and distribution access, improving revenue predictability and partner-driven scale.
Revenue Rebound And Steady Gross MarginConsistent top-line improvement with stable ~37%–38% gross margins shows the core HOCl product economics hold up as volumes recover. This combination supports longer-term operating leverage potential and indicates the business model can expand revenue without immediate gross margin erosion.
Modest Leverage / Low DebtLow financial leverage reduces immediate solvency risk and gives the company flexibility to fund operations via modest additional debt if needed. In a cash-burning stage, limited fixed interest burdens preserve more optionality for strategic investments or contractual fulfilment.
Bears Say
Persistent Cash BurnNegative operating and free cash flow across recent periods signals structural cash-generation weakness. Continued burn forces reliance on external financing, increases dilution risk, and constrains the company's ability to invest in commercialization or R&D without repeat capital raises.
Ongoing UnprofitabilitySustained negative net margins mean the business has yet to convert revenue growth into lasting profitability. This limits internal funding for expansion, raises questions about scale economics, and keeps profitability sensitive to volume swings and cost-side pressures.
Shrinking Equity BaseMaterial decline in shareholders' equity reduces the balance-sheet cushion against setbacks and heightens the need for external capital. A smaller equity base amplifies dilution from future financings and weakens the company's ability to absorb operational or commercial shocks over the medium term.
Sonoma Pharmaceuticals News
O8Z FAQ
What was Sonoma Pharmaceuticals, Inc.’s price range in the past 12 months?
Sonoma Pharmaceuticals, Inc. lowest stock price was €2.69 and its highest was €2.96 in the past 12 months.
What is Sonoma Pharmaceuticals, Inc.’s market cap?
Sonoma Pharmaceuticals, Inc.’s market cap is €3.32M.
When is Sonoma Pharmaceuticals, Inc.’s upcoming earnings report date?
Sonoma Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Sonoma Pharmaceuticals, Inc.’s earnings last quarter?
Sonoma Pharmaceuticals, Inc. released its earnings results on Jun 16, 2026. The company reported -€0.284 earnings per share for the quarter, missing the consensus estimate of -€0.207 by -€0.077.
Is Sonoma Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Sonoma Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Sonoma Pharmaceuticals, Inc. pay dividends?
Sonoma Pharmaceuticals, Inc. does not currently pay dividends.
What is Sonoma Pharmaceuticals, Inc.’s EPS estimate?
Sonoma Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sonoma Pharmaceuticals, Inc. have?
Sonoma Pharmaceuticals, Inc. has 3,473,554 shares outstanding.
What happened to Sonoma Pharmaceuticals, Inc.’s price movement after its last earnings report?
Sonoma Pharmaceuticals, Inc. reported an EPS of -€0.284 in its last earnings report, missing expectations of -€0.207. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Sonoma Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in DE:O8Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
Technical Analysis
China Pharma Holdings
―
―
RedHill Biopharma
―
Sunshine Biopharma
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Options Prices
Currently, No data available
---